Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesAnteris Technologies Global Corp

Anteris Technologies Global Corp

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
8.2 AUD -0.36 ( 4.21%)
Last update at 2026-11-06T01:07:00Z
VOLUME
5921
Market Cap
798.21M

Momentum Score

…

Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
8.05
Low
8.30
High
52 Week Price Range
5.20
Low
15.47
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Anteris Technologies Global Corp is an Australian medical device company developing and commercializing tissue-based cardiovascular implants with a focus on anatomically engineered heart valve solutions. Long-term growth drivers include clinical and regulatory progress, commercialization and manufacturing scale-up, and demographic tailwinds for structural heart disease; investors may find exposure to a differentiated tissue-engineering approach and a sizable addressable valve market attractive.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
8.56
Dividend Yield
-
Revenue TTM
2.24M
Revenue Per Share
0.04
Gross Profit TTM
1.68M
Debt / Equity
0.02
ROE
-74.65%
Net Debt
0.04M
ROCE
-5796.55%
Diluted EPS TTM
-2.88

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -94.22M -122.74M -70.45M -44.34M -22.91M
Minority interest 0.08M -0.32M 1.56M - -
Net income -94.14M -123.26M -67.33M -45.25M -25.77M
Selling general administrative 26.12M 17.35M 23.83M 22.45M 13.95M
Selling and marketing expenses - 28.19M 1.12M 1.18M 0.55M
Gross profit 1.34M -0.37M -0.42M 2.61M 6.15M
Reconciled depreciation 1.66M 1.30M 2.79M 1.74M 1.35M
Ebit - -114.40M -69.69M -43.43M -21.57M
Ebitda - -112.11M -66.90M -41.69M -20.21M
Depreciation and amortization - 2.28M 2.79M 1.74M 1.35M
Operating income -94.14M -126.63M -71.37M -43.43M -21.57M
Other operating expenses - 130.99M 75.49M 51.98M 30.80M
Interest expense 0.07M 0.05M 0.10M 0.91M 1.34M
Tax provision 0.00M 0.00M -0.19M 0.00M 0.00M
Interest income 0.71M 0.43M 0.64M 0.31M 0.09M
Net interest income 0.64M 0.38M 0.17M -0.77M -1.42M
Income tax expense - - -0.13M 0.91M 2.86M
Total revenue 1.91M 4.37M 4.11M 4.59M 7.79M
Total operating expenses 96.05M 118.45M 70.99M 49.99M 29.16M
Cost of revenue 0.57M 4.46M 4.54M 1.98M 1.64M
Total other income expense net -0.72M 3.89M 0.92M -0.91M -1.34M
Net income from continuing ops -94.22M -75.97M -68.89M -44.34M -22.91M
Net income applicable to common shares - - - -44.34M -22.91M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 23.00M 130.39M 45.70M 23.48M 29.48M
Intangible assets - 0.31M - 0.90M 1.15M
Other current assets - 5.33M 3.14M 1.40M 1.20M
Total liab 23.25M 29.11M 17.04M 10.26M 15.13M
Total stockholder equity -0.09M 101.40M 28.60M 13.22M 14.35M
Other current liab - 16.03M 8.26M 4.23M 4.56M
Common stock - 0.01M 282.99M 211.83M 172.64M
Capital stock 0.00M 350.04M - 211.83M 172.64M
Retained earnings -370.53M -446.56M -270.42M -202.02M -157.68M
Other liab - - - 2.07M 1.77M
Other assets - - 0.00M - -
Cash - 113.84M 30.83M 13.81M 21.30M
Total current liabilities 21.37M 26.76M 13.83M 7.54M 12.94M
Current deferred revenue - 0.00M - - -
Net debt 0.04M -111.59M -28.50M -12.40M -15.57M
Short term debt - 1.21M 0.98M 0.76M 5.31M
Short long term debt 0.02M 0.00M - - 4.68M
Short long term debt total - 2.25M 2.33M 1.41M 5.73M
Other stockholder equity - 565.55M - -1.51M -0.61M
Property plant equipment - - - 4.52M 2.50M
Total current assets 15.68M 120.61M 35.89M 18.07M 25.84M
Net tangible assets - - - 12.32M 13.20M
Short term investments - - - 0.09M 0.09M
Net receivables 0.03M 0.62M 1.27M 0.83M 2.59M
Long term debt 0.02M - - 1.38M 1.21M
Inventory 0.15M 0.83M 0.65M 0.52M 0.76M
Accounts payable 11.09M 9.51M 4.59M 2.55M 3.07M
Accumulated other comprehensive income - -17.60M 16.04M 3.41M -0.61M
Non currrent assets other - 0.00M 1.38M - -
Non current assets total 7.32M 9.77M 9.81M 5.41M 3.64M
Capital lease obligations 2.24M 1.39M - 1.41M 1.05M
Long term debt total - - - 2.03M 1.63M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -2.28M -3.90M -1.36M -0.40M
Change to liabilities - - - 0.53M 1.50M
Total cashflows from investing activities - -3.46M -3.90M -1.36M -1.16M
Net borrowings -1.24M -2.24M -1.34M -2.06M 1.15M
Total cash from financing activities 20.55M 171.06M 72.95M 31.36M 36.91M
Change to operating activities - - - 0.30M -0.07M
Net income -94.14M -123.26M -67.52M -45.25M -22.91M
Change in cash -57.88M 82.90M 17.03M -7.49M 16.95M
Begin period cash flow 70.46M 30.94M 13.81M 21.30M 4.35M
End period cash flow 12.58M 113.84M 30.83M 13.81M 21.30M
Total cash from operating activities -77.80M -92.85M -51.43M -43.51M -18.81M
Issuance of capital stock 25.82M 115.73M 78.93M 34.89M 36.85M
Depreciation 1.66M 3.19M 2.79M 1.74M 1.35M
Other cashflows from investing activities - 0.20M 0.03M 1.05M -0.39M
Dividends paid - - - - 5.00M
Change to inventory 0.36M -0.11M -0.13M 0.23M -0.06M
Change to account receivables -0.52M -1.47M -0.52M -0.98M -0.05M
Sale purchase of stock - - -4.02M -1.47M -1.09M
Other cashflows from financing activities - 58.95M -0.82M -0.71M 8.94M
Change to netincome - - - 2.80M 0.41M
Capital expenditures 1.95M 3.66M 3.56M 2.41M 0.77M
Change in working capital 6.26M -1.59M 6.01M 1.85M 1.60M
Stock based compensation 7.78M - 9.54M - -
Other non cash items -0.03M 32.00M -2.24M 43.51M 21.55M
Free cash flow -79.76M -102.61M -55.00M -45.92M -19.58M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
AVR
Anteris Technologies Global Corp		 -0.36
4.21%		 8.20 - - 356.02 2.19 130.34 -5.20
COH
Cochlear Ltd		 1.03
0.67%		 155.47 68.64 27.40 4.30 5.34 3.97 28.09
IMR
Imricor Medical Systems Inc		 -0.03
2.29%		 1.28 - - 36401.21 17.45 4019.33 -2.60
AVH
Avita Medical Inc		 -0.08
1.73%		 4.55 - 9.97 9.59 7.17 6.76 15.37
PNV
Polynovo Ltd		 -0.01
1.66%		 0.89 90.50 90.91 4.17 6.67 4.08 54.57

Profile*

Anteris Technologies Global Corp

Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.

Toowong Tower, Toowong, QLD, Australia, 4066

61 7 3152 3200

https://anteristech.com

174

Name Title Year Born
Mr. Wayne G. Paterson CEO, MD & Exec. Director 1967
Mr. Matthew McDonnell Chief Financial Officer NA
Mr. David St. Denis Chief Operating Officer NA
Mr. Stephen Denaro Independent Non-Exec. Director & Company Sec. NA
Mr. Chris Olig Bus. Devel. and Portfolio Planning Director NA
Dr. Chris Meduri M.D., M.P.H. Chief Medical Officer & Member of Medical Advisory Board NA
Mr. Danny Zanardo Commercial Director of International NA
Prof. Ian Hector Frazer AC, FAA, FRS, M.D. Exec. NA
Mr. Wayne G. Paterson CEO, MD & Executive Director 1967
Mr. Stephen Denaro Independent Non-Executive Director & Company Secretary NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…